Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
8.0
来源：
Nature
关键字：
ADC
发布时间：
2025-10-08 23:59
摘要：
The DESTINY-Breast04 trial results indicate that trastuzumab deruxtecan (T-DXd) significantly enhances overall and progression-free survival in patients with HER2-low metastatic breast cancer compared to traditional chemotherapy options. With a median overall survival of 22.9 months for T-DXd versus 16.8 months for the treatment of physician's choice, T-DXd is positioned as a new standard of care. The trial's findings support the clinical efficacy of T-DXd and highlight its potential as a valuable investment opportunity in oncology, particularly for patients previously treated with chemotherapy.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
1.0
关键证据
T-DXd significantly improved overall survival (OS) and progression-free survival (PFS) compared with treatment of physician’s choice.
Median OS in the overall cohort was 22.9 months for T-DXd versus 16.8 months for TPC.
T-DXd has been approved by regulatory bodies for HER2-low unresectable or metastatic breast cancer.
真实性检查
否
AI评分总结
The DESTINY-Breast04 trial results indicate that trastuzumab deruxtecan (T-DXd) significantly enhances overall and progression-free survival in patients with HER2-low metastatic breast cancer compared to traditional chemotherapy options. With a median overall survival of 22.9 months for T-DXd versus 16.8 months for the treatment of physician's choice, T-DXd is positioned as a new standard of care. The trial's findings support the clinical efficacy of T-DXd and highlight its potential as a valuable investment opportunity in oncology, particularly for patients previously treated with chemotherapy.